Dr. Robert Hindes recently served as the Vice President of Clinical Development with Pharmasset, Inc. in Princeton, New Jersey. When he assumed the role in 2011, Dr. Hindes took charge of clinical development for Pharmasset's hepatitis C antiviral nucleosides. He was responsible for design and execution of all Phase 2 clinical trials, while coordinating with regulatory agencies in the United States and Europe. In 2012, Dr. Robert Hindes left the company after its sale to Gilead Sciences. Before his work at Pharmasset, Dr. Hindes was Group Director of Virology at Bristol-Myers Squibb, in Wallingford, Connecticut. Over the course of a decade, he oversaw the development and clinical trials of hepatitis C antiviral drugs, and served as Medical Lead for the late Phase development of all hepatitis C antiviral drugs. He also played an integral role in the New Drug Application (NDA) for Entecavir (Baraclude), which treats chronic hepatitis B. An expert in infectious diseases, Dr. Robert Hindes completed both clinical and research fellowships in his specialty at Harvard Medical School and New England Deaconess Hospital. He did a residency and an internship at the Medical College of Pennsylvania Hospital, in Philadelphia.Dr. Robert Hindes has held active medical licensure in Connecticut for more than two decades. He is a Diplomate in the American Board of Internal Medicine and in the Subspecialty of Infectious Disease. Dr. Hindes has authored more than 80 publications and abstracts presented at scientific meetings. An alumnus of Rutgers Medical School, Dr. Hindes graduated with a Doctor of Medicine and received a Bachelor of Arts from Rutgers University. An avid hiker and skier, Dr. Hindes spends much of his free time outdoors. He also enjoys music and the arts.
Mar 2011 - Jan 2012
Vice President Clinical Development
Responsible for strategic design and successful execution of all Phase 2 and 3 clinical trials.
Design and execution of clinical trials, responsible for regulatory responses and interactions with FDA and European regulators.
Led Pharmasset team which participated in extremely successful face-to-face End of Phase 2 meeting with FDA.
2001 - 2011
Group Director Virology
Medical Lead for Hep C anti-viral drugs Full Development Team.
Responsible for development of overall strategy of clinical program, design and conduct of all Phase 2 and 3 clinical trials, interaction with FDA and all regulatory agencies in Europe, Asia, and South America. Major role in successful NDA for entecavir (Baraclude) in 2005.